质子泵抑制剂安全性的伞状综述:42项系统评价与荟萃分析
该伞状综述纳入42项系统评价与荟萃分析,以观察性证据为主,评估PPI使用与不良结局的关联。研究报告PPI使用与骨折、肾病、感染、胃癌及胃肠道事件存在统计学显著关联,但GRADE证据确定性多为极低,需进一步研究明确临床意义与因果可能性。
要点
- PPI使用与骨折、急性肾损伤、艰难梭菌感染、胃癌及胃底腺息肉等存在显著关联。
- 大多数结局的GRADE证据确定性为极低,因果关联尚不明确。
- 若更高质量证据证实风险,临床或需在PPI疗效欠佳时考虑替代策略。
核心结论
- 本伞状综述发现PPI使用与多种不良结局存在已发表的统计学显著关联,但证据确定性多为极低,临床意义与因果关系需进一步研究。
研究设计与样本
- 按照PRISMA开展伞状综述,检索PubMed和EMBASE(2015年至2019年7月)的系统评价与荟萃分析,使用AMSTAR 2和GRADE评估质量与证据确定性。
主要发现
- 共纳入42项系统评价与荟萃分析,证据主要来自观察性研究。
- 骨折(如髋部)RR=1.20,95%CI=1.14-1.28,n=2 103 800。
- 肾脏疾病(如急性肾损伤)RR=1.61,95%CI=1.16-2.22,n=2 396 640。
- 感染(如艰难梭菌)OR=1.99,95%CI=1.73-2.30,n=356 683。
- 胃癌OR=2.50,95%CI=1.74-3.85,n=943 070;胃肠道事件(如胃底腺息肉)OR=2.46,95%CI=1.42-4.27,n=40 218。
关键数值与推荐
- GRADE评估显示大多数结局的证据确定性为极低。
- 未得出与非胃癌或神经系统疾病的关联结论,心血管结局证据存在矛盾。
临床怎么用
- 临床应关注PPI长期使用的潜在风险,尤其在PPI疗效欠佳时可考虑替代治疗策略,但需结合证据确定性极低的现状审慎决策。
局限性
- 纳入证据以观察性研究为主,GRADE证据确定性多为极低,难以确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton pump inhibitors (PPIs) are widely used to treat and prevent acid-related disorders. Despite high efficacy, PPI safety has been increasingly scrutinised. However, no comprehensive review summarising investigations of various adverse events is available. AIMS: To perform an umbrella review to comprehensively assess associations between adverse events and PPI use. METHODS: In accordance with PRISMA, an umbrella review of systematic reviews with meta-analyses was conducted. PubMed and EMBASE were searched from 2015 to July 2019. AMSTAR 2 and GRADE were used to assess quality and certainty of evidence. Author-reported quality assessments were also reviewed. RESULTS: Forty-two systematic reviews with meta-analyses, supported predominantly by observational evidence, were included. The most comprehensive studies reported statistically significant associations with PPI use for several outcomes, including: fractures (eg, hip; RR = 1.20; 95% CI = 1.14-1.28; n = 2 103 800), kidney disease (eg, acute kidney injury; RR = 1.61; 95% CI = 1.16-2.22; n = 2 396 640), infections (eg, Clostridioides difficile; OR = 1.99; 95% CI = 1.73-2.30; n = 356 683), gastric cancer (OR = 2.50; 95% CI = 1.74-3.85; n = 943 070) and gastrointestinal events (eg, fundic gland polyps; OR = 2.46; 95% CI = 1.42-4.27; n = 40 218). No associations with non-gastric cancers, or neurological disease were concluded, with conflicting evidence for cardiovascular outcomes. Certainty based on GRADE was very low for most outcomes. CONCLUSIONS: This review identified several published associations between PPIs and adverse outcomes, however, further investigation is needed to understand their clinical significance and the likelihood of causal relationship. If higher quality evidence is generated substantiating the potential risks, it may be necessary for clinicians to consider alternative treatment strategies, especially when PPI efficacy is suboptimal.
引用
- Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021. PMID: 34114655. doi:10.1111/apt.16407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。